ClinicalTrials.gg
RecruitingNCT05321316Updated Nov 18, 2026

Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors

An interventional study of 18F-FDG in Urothelial Carcinoma, Breast Cancer and Lung Cancer, sponsored by Peking University Cancer Hospital & Institute. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Peking University Cancer Hospital & Institute · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 18, 2026Start date movedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Carcinoma, Transitional Cell with a site in China — 53 open to participants now, 58 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.

Planned enrollment
53rd of 71
40 · median 58
Started
2025
with 13 others
No phase
4 of 90
4 open now
Primary completion
2026-12
later than 19 of 57 live
Registered
30th of 90
by date

Among the 90 studies in Carcinoma, Transitional Cell with a site in China, this one is the 53rd largest by planned enrollment of the 71 interventional ones that give a count, is one of 14 that started in 2025, is one of 4 with no phase, reaches primary completion later than 19 of the 57 other live ones, and was the 30th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

53 of the 90 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Carcinoma, Transitional Cell with a site in China, or all of them as a file.
02

Study summary

To evaluate the ability of [68Ga]NT-CBH to detect nectin-4 overexpression in subjects with urinary system cancers, breast cancer, lung cancer, pancreatic cancer, gastrointestinal cancer, and ovarian cancer.

03

Conditions studied

  • Urothelial Carcinoma
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Gastrointestinal Cancers
  • Ovarian Cancer
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-75 years old, male or female;
  2. Routine blood tests, coagulation function, and liver/kidney function must meet the acceptable levels specified in the protocol; indicators including WBC, neutrophils, , , PT/, T-Bil, /AST, ALP, BUN, and SCr must meet the protocol requirements. For participants with liver or bone , related indicators such as ALP may be appropriately relaxed according to the protocol;
  3. Normal heart function;
  4. Estimated survival ≥12 weeks;
  5. Good follow-up compliance;
  6. presence of at least one measurable target lesion according to RECIST1.1 criteria;
  7. Women of childbearing age (15-49 years) must be assessed by the investigator as having no possibility of pregnancy before the examination begins; Fertile male and female participants must agree to use effective to prevent pregnancy during the study and for 3 months after the examination;
  8. Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;
  9. The subject patients could fully understand and voluntarily participate in the experiment, and signed the .

Exclusion criteria

Exclusion Criteria:

  1. Serious abnormality of liver, kidney and blood;
  2. Pregnant patients;
  3. Pregnant and lactation women;

3) unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    68Ga-NT-BCH

    Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-NT-BCH PET/CT scan.

    Drug: 18F-FDG

Interventions

  • Drug18F-FDG

    All study participants will undergo one 18F-FDG PET/CT scan.

06

What researchers measure

Primary outcomes

  1. Standardized uptake value(SUV)

    SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has a certain reference value for differentiating benign and malignant lesions. The uptake of the tracer (68Ga-NT-BCH) in solid tumors will be evaluated by measuring SUV on PET/CT.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 29 interventional studies with no phase under Carcinoma, Transitional Cell, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 23. This study's planned 19 months is below that.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → May 2025, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2022
First posted
Apr 11, 2022
StartActual
May 31, 2025was May 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 31, 2026→May 31, 2025 (actual)
Nov 18, 2026
Enrollment
20→40
Nov 18, 2026
Eligibility
1 inclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedHeart function is normal;
  • AddedRoutine blood tests, coagulation function, and liver/kidney function must meet the acceptable levels specified in the protocol; indicators including WBC, neutrophils, PLT, Hb, PT/APTT, T-Bil, ALT/AST, ALP, BUN, and SCr must meet the protocol requirements. For participants with liver or bone metastases, related indicators such as ALP may be appropriately relaxed according to the protocol;
  • EditedWomen of childbearing age (15-49 years) must have a negativebe assessed by the investigator as having no possibility of pregnancy test within 7 days before starting the testexamination begins; Fertile menmale and womenfemale participants must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the testexamination;
Nov 18, 2026
Interventions
Arm changed 68Ga-N188→68Ga-NT-BCH
Nov 18, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionStandardized uptake value(SUV): how it is measured was reworded
Nov 18, 2026
Title
Nectin-4 Specific LMW PET Probe Imaging in Urothelial CarcinomaMultiple Solid Tumors
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date May 31, 2026→May 31, 2025 (now actual)
    Enrollment 20→40
    Eligibility 1 inclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedHeart function is normal;
    • AddedRoutine blood tests, coagulation function, and liver/kidney function must meet the acceptable levels specified in the protocol; indicators including WBC, neutrophils, PLT, Hb, PT/APTT, T-Bil, ALT/AST, ALP, BUN, and SCr must meet the protocol requirements. For participants with liver or bone metastases, related indicators such as ALP may be appropriately relaxed according to the protocol;
    • EditedWomen of childbearing age (15-49 years) must have a negativebe assessed by the investigator as having no possibility of pregnancy test within 7 days before starting the testexamination begins; Fertile menmale and womenfemale participants must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the testexamination;
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionStandardized uptake value(SUV): how it is measured was reworded
    Interventions Arm changed 68Ga-N188→68Ga-NT-BCH
    Title Nectin-4 Specific LMW PET Probe Imaging in Urothelial CarcinomaMultiple Solid Tumors
    + 4 other changes: verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05321316
Responsible party
Hua Zhu (Professor, Peking University Cancer Hospital & Institute) — Principal investigator
First posted
Apr 11, 2022
Start date
May 31, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Zhi Yang, Professor
Contact
pekyz@163.com
010-88196495
Hua Zhu, Professor
Contact
zhuhuabch@pku.edu.cn
010-88196495

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion